Crossject specialises in needle-free, high-pressure drug delivery through its proprietary Zeneo platform. Its flagship drug-device combination, Zepizure, is an auto-injectable midazolam intended for the rapid management of epileptic seizures. The company is currently preparing for an Emergency Use Authorization filing with the U.S. FDA, which analysts expect to be submitted by the end of 2025. To bridge operations until anticipated BARDA orders in early 2026, Crossject has been actively raising capital, including €5.7 million from a market placement before the summer and $11.3 million in September from the U.S. Biomedical Advanced Research and Development Authority (BARDA). The latest €5 million convertible bond financing extends its cash runway while minimising dilution, as full conversion would represent only about 3.65 % of outstanding shares. An Invest Securities analyst maintains a Buy rating with a €3.30 price target, citing sufficient funding to reach the next regulatory and commercial milestones.

Total raised

$17M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Nov 2025